相关实验视频
Updated: Jun 27, 2025

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.5K
口服一氧化碳对多克索鲁比诱导的心脏毒性的有益影响
Rodrigo W Alves de Souza1, Vanessa Voltarelli1, David Gallo1
1Department of Surgery Beth Israel Deaconess Medical Center, Harvard Medical School Boston MA USA.
Journal of the American Heart Association
|May 3, 2024
概括
在癌症患者中,一种新的口服一氧化碳 (CO) 药物HBI-002有效地保护心脏免受多克索鲁比毒性. 这种新的配方保持了化疗的疗效,同时预防了心脏损伤.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多克索鲁比 (化疗药物) 引起心脏毒性,限制了治疗.
- 低碳一氧化物 (CO) 已显示出心脏保护作用.
- 现有的CO输送方法对于患者的使用是不切实际的.
研究的目的:
- 开发和评估一种口服的CO药物 (HBI-002),用于杜克索鲁比诱导的心脏毒性.
- 评估HBI-002的安全性,有效性和对化疗有效性的影响.
主要方法:
- 在 doxorubicin 治疗前,HBI-002 被口服给小鼠模型.
- 测量了心脏组织中的碳氧血球水平和CO度.
- 评估了心脏功能,组织损伤,瘤体积和生存率.
主要成果:
- HBI-002在心脏组织中增加了CO水平,并提高了血红氧酶-1的调节.
- 它显著地保护了急性和慢性多克索鲁比辛心脏毒性,改善了心脏功能和存活率.
- 在乳腺癌模型中,HBI-002并没有降低多克索鲁比辛的抗瘤功效,并且增强了乳腺癌模型的敏感性.
结论:
- HBI-002是一种有前途的心脏保护剂,用于接受多克索鲁比治疗的癌症患者.
- 它有效地减轻心脏损伤,同时保持化疗的好处.
相关概念视频
Heart Failure Drugs: Inotropic Agents
574
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
574
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Electron Transport Chain: Complex I and II
13.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.1K
Oxygen Transport in the Blood
2.7K
Hemoglobin (Hb) is a crucial molecule in the human body, consisting of four polypeptide chains, each bound to an iron-containing heme group. This unique structure enables hemoglobin to bind to oxygen, with each molecule capable of combining with four molecules of oxygen, leading to rapid and reversible oxygen loading. When fully loaded with oxygen, it is called oxyhemoglobin, while hemoglobin that has released oxygen is called reduced hemoglobin or deoxyhemoglobin. As hemoglobin binds oxygen,...
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422

